Erratum: Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality (JAMA - Journal of the American Medical Association (2013) 309, 1 (48-54) DOI: 10.1001/jama.2012.153812);Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality

JAMA

Volumn 309, Issue 1, 2013, Pages 48-54

  Stephansson, Olof ^a   Kieler, Helle ^a   Haglund, Bengt ^a   Artama, Miia ^c   Engeland, Anders ^d,e   Furu, Kari ^d,f   Gissler, Mika ^b,c   Nørgaard, Mette ^g   Nielsen, Rikke Beck ^g   Zoega, Helga ^h,j   Valdimarsdóttir, Unnur ^h,i  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY OF TROMSØ   (Norway)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY OF ICELAND   (Iceland)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FINLAND; HOSPITALIZATION; HUMAN; HYPERTENSION; ICELAND; INFANT MORTALITY; MAJOR CLINICAL STUDY; MATERNAL AGE; NEWBORN DEATH; NORWAY; PERINATAL DRUG EXPOSURE; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; PUERPERAL DEPRESSION; REGISTER; RISK ASSESSMENT; RISK FACTOR; SMOKING; STILLBIRTH; SWEDEN;

EID: 84871813839     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.4527     Document Type: Erratum

References (27)

1. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ. 2001;323(7307):257-260.
2. Lee AM, Lam SK, Sze Mun Lau SM, Chong CS, Chui HW, Fong DY. Prevalence, course, and risk factors for antenatal anxiety and depression. Obstet Gynecol. 2007;110(5):1102-1112.
3. Alder J, Fink N, Bitzer J, Hösli I, Holzgreve W. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? a critical review of the literature. JMatern Fetal Neonatal Med. 2007;20(3):189-209.
4. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31(5):403-413.
5. Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166(5):557-566.
6. Bakker MK, Kölling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65(4):600-606.
7. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675-2683.
8. Hemels ME, Einarson A, Koren G, Lanctôt KL, Einarson TR. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother. 2005;39(5):803-809.
9. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365(9458):482-487.
10. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012;344:d8012.
11. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-587.
12. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010;44(11):978-996.
13. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499-507.
14. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug use during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical Birth Register. Clin Epidemiol. 2011;3:43-50.
15. Nilsson E, Hultman CM, Cnattingius S, Olausson PO, Björk C, Lichtenstein P. Schizophrenia and offspring's risk for adverse pregnancy outcomes and infant death. Br J Psychiatry. 2008;193(4):311-315.
16. Gentile S. Pregnancy exposure to serotonin reuptake inhibitors and the risk of spontaneous abortions. CNS Spectr. 2008;13(11):960-966.
17. Rosén M. National Health Data Registers: a Nordic heritage to public health. Scand J Public Health. 2002;30(2):81-85.
18. Gissler M, Louhiala P, Hemminki E. Nordic Medical Birth Registers in epidemiological research. Eur J Epidemiol. 1997;13(2):169-175.
19. Høgberg U, Larsson N. Early dating by ultrasound and perinatal outcome: a cohort study. Acta Obstet Gynecol Scand. 1997;76(10):907-912.
20. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86-94.
21. Munk-Jørgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44(1):82-84.
22. Agency DM. Risk of death or serious side effects in newborns following exposure to antidepressants (fluoxetine and other SSRIs). 2011; http://laegemiddelstyrelsen.dk/en/topics/side-effects-and-trials/side-effects/ news/risk-of-death-or-serious-side-effects-in--ther-ssris. Accessed December 7, 2012.
23. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279(8):609-610.
24. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in Western Australia. CNS Drugs. 2012;26(7):e1-e14.
25. Klieger-Grossmann C, Weitzner B, Panchaud A, et al. Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. J Clin Pharmacol. 2012;52(5):766-770.
26. Chalmers JW, Shanks E, Paterson S, McInneny K, Baird D, Penney G. Scottish data on intrapartum related deaths are in same direction as Welsh data. BMJ. 1998;317(7157):539-540.
27. Cnattingius S. The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res. 2004;6(suppl 2):S125-S140.